CollaGenex Pharmaceuticals (CGPI) Reports Q4 EPS of $0.02
CollaGenex Pharmaceuticals Inc. (Nasdaq: CGPI) reports Q4 earnings of $0.02 per share, below the consensus of a $0.18 loss. Revenues came in at $17 million, versus the consensus of $15.2 million.
CollaGenex Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets proprietary medical therapies to the dermatology market.
CollaGenex Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets proprietary medical therapies to the dermatology market.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Infoblox (BLOX) Tops Q3 EPS by 4c; Guides Q4
- VeriFone Systems (PAY) Tops Q2 EPS by 3c; Guides Q3, FY12
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
